-

12:13:26 PM

Latest TCON Stock Market News

TCON - TRACON Pharmaceuticals Inc

07/28/21 8:05 AM

Nasdaq : TCON

conferencesearnings

TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

07/21/21 10:30 PM

Nasdaq : TCON

offering

TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that, due to demand, the underwriter

RHEA-AI

neutral

07/21/21 5:27 PM

Nasdaq : TCON

offering

TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that it has entered into an

RHEA-AI

neutral

07/20/21 8:05 AM

Nasdaq : TCON

management

TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

very positive

06/30/21 8:05 AM

Nasdaq : TCON

management

TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

very positive

06/29/21 8:05 AM

Nasdaq : TCON

TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of

RHEA-AI

very positive

06/04/21 9:01 AM

Nasdaq : TCON

clinical trial

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the Company’s Phase 1 study of TJ004309 and

RHEA-AI

neutral

06/01/21 8:05 AM

Nasdaq : TCON

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent

RHEA-AI

neutral

05/25/21 8:05 AM

Nasdaq : TCON

conferences

TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

05/20/21 8:05 AM

Nasdaq : TCON

TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

TCON Data

industryBiological Product (except Diagnostic) Manufacturing
websitewww.traconpharma.com
ceo
security nameTRACON Pharmaceuticals Inc
issue typecs
sectorManufacturing
sic code2836
employees
tagsHealth Technology,Biotechnology,Manufacturing,Biological Product (except Diagnostic) Manufacturing
address
address2
state
city
zip
country
phone

TCON Description:

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company's clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.